Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
On November 16, 2026, Alpha Tau Medical Ltd. (the
“Company”) held a previously announced investor call to discuss new results from its REGAIN trial. A copy of the presentation
used during the call is furnished as Exhibit 99.1 to this Report on Form 6-K.
The information in this Report on Form 6-K, including
Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth
by specific reference in such a filing.
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Exhibit 99.1

N A S D A Q / T A S E · D R T S R E G A I N · I N T E R I M R E S U L T S A S O F N O V 1 1 , 2 0 2 6 Alpha DaRT in the brain. Interim results as of November 11, 2026 from REGAIN, the U.S. trial of Alpha DaRT in recurrent glioblastoma, as presented at the SNO 2026 Annual Meeting. 8 of 8 patients alive · 100% feasibility · 6 of 6 objective responses in assessed patients 1

D I S C L A I M E R Important notices. This presentation (together with oral statements made in connection herewith, the "Presentation") is for informational purposes only to assist interested parties in making their own evaluation with respect to Alpha Tau Medical Ltd. ("Alpha Tau" or the "Company"). The information contained herein does not purport to be all-inclusive and neither the Company nor any of its respective subsidiaries, stockholders, shareholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents make any representation or warranty, express or implied, as to the accuracy, completeness or reliability of the information contained in this Presentation. You should consult your own counsel and tax and financial advisors as to legal and related matters concerning the matters described herein, and, by accepting this Presentation, you confirm that you are not relying upon the information contained herein to make any decision. To the fullest extent permitted by law, in no circumstances will the Company or any of its subsidiaries, stockholders, shareholders, affiliates, representatives, partners, directors, officers, employees, advisers or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Presentation, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. The general explanations included in this Presentation cannot address, and are not intended to address, your specific investment objectives, financial situations or financial needs. Use of Data Certain information contained in this Presentation relates to or is based on studies, publications, surveys and the Company's own internal estimates and research. In addition, all of the market data included in this Presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While the Company believes its internal research is reliable, such research has not been verified by any independent source and neither the Company nor any of its affiliates, officers, directors, employees or representatives make any representation or warranty with respect to the accuracy of such information. Trademarks This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM © or ® symbols, but Alpha Tau will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Forward-Looking Statements This presentation contains forward-looking statements, including without limitation, statements related to: Alpha Tau becoming the leader in delivering innovative devices in medical technology, our ability to expand our development pipeline, opportunities to expand our portfolio through partnerships and collaborations, the progress, timing and results of our clinical trials, the safety and efficacy of our development programs, the timing of potential approvals of our products, the timing and commercial success of our products, strategies for completion and likelihood of success for our business and activities, size and growth of markets in which we may compete and potential market opportunity, and potential growth opportunities. Forward-looking statements can be identified by the words "believe," "anticipate," "continue," "estimate," "project," "expect," "plan," "potential," "intends," "will," "would," "could," "should" or the negative or plural of these words or other similar expressions that are predictions or indicate future events, trends or prospects but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, among others, those inherent in the preclinical and clinical development process and the regulatory approval process, the risks and uncertainties in commercialization and gaining market acceptance, the risks associated with protecting and defending our patents or other proprietary rights, the risk that our proprietary rights may be insufficient to protect our development programs, the risk that we will be unable to obtain necessary capital when needed on acceptable terms or at all, competition from other products or procedures, our reliance on third parties to conduct our clinical and non-clinical trials, our reliance on any third-party suppliers to manufacture clinical, non-clinical and any future commercial supplies of our products, and increased regulatory requirements. These statements are subject to the risk that clinical trial data are subject to differing interpretations, and regulatory agencies, medical and scientific experts and others may not share Alpha Tau's views of the clinical study data. There can be no assurance that the clinical studies for our development programs will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that any of our products will ever receive regulatory approval or be successfully commercialized. These forward-looking statements are based on information available to Alpha Tau as of the date of this Presentation and speak only as of the date of this Presentation. For a discussion of risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see Alpha Tau's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 20-F and subsequent filings. Alpha Tau disclaims any obligation to update these forward-looking statements, except as may be required by law. This Presentation is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to purchase any securities of any nature whatsoever, and it may not be relied upon in connection with the purchase of securities. 2

T O D A Y ' S P R E S E N T E R S Today's presenters. 3 Uzi Sofer CEO, Alpha Tau Raphi Levy CFO, Alpha Tau Robert Den, MD Chief Medical Officer, Alpha Tau Joshua Palmer, MD Professor, Radiation Oncology · Principal Investigator, REGAIN Ohio State University Comprehensive Cancer Center - The James Alpha Tau Medical Ltd. · NASDAQ / TASE: DRTS · Conference call and webcast, Monday, November 16, 2026, 8:30 a.m. ET

A G E N D A What we will cover. 4 01 Alpha DaRT mechanism of action Why alpha radiation, how Alpha DaRT is designed to extend its reach, and the Alpha radial applicator for the brain. 02 Interim results from REGAIN as of Nov 11, 2026 Trial design, feasibility and safety, survival and tumor response, as presented at the SNO 2026 Annual Meeting. 03 Patient by patient Imaging and clinical course for each of the six assessed patients, including what the follow-up scans can and cannot yet tell us. 04 Summary and Q&A What the data show, what is still being evaluated, and what comes next.

0 1 · T H E S C I E N C E Alpha DaRT: mechanism of action. 5

T H E S C I E N C E · W H Y A L P H A Why alpha radiation. Two kinds of radiation, two kinds of DNA damage. 6 Conventional gamma / beta radiation Damages DNA indirectly, through free radicals Dependent on the presence of oxygen Causes repairable single-strand breaks Alpha radiation Damages DNA directly Independent of oxygen Causes irreparable double-strand breaks γ/β radiation → O₂ → free radicals → single-strand breaks α radiation → direct double-strand breaks

T H E S C I E N C E · T H E P R O B L E M Cancer's most potent radiation had a range problem. 7 <0.1 mm alpha-particle range in tissue: about the width of a human hair Alpha particles are massively destructive at point-blank range and spare what lies beyond it, but they could not reach far enough into a tumor to matter. For a century, that made alpha radiation effectively unusable against solid tumors. α Alpha: point-blank power, no reach Treats only a hair's width around the emitter; the rest of the tumor is out of reach. β γ Beta & gamma: reach, at a cost Reaches the whole tumor, and the healthy tissue beyond it. Blocked by a sheet of paper Alpha particles are stopped by a sheet of paper, or a fraction of a millimeter of tissue. Beta and gamma penetrate much further: useful for reach, costly for everything in the way. The trade-off that defined radiotherapy: reach the tumor and expose healthy tissue, or spare it and never arrive.

T H E S C I E N C E · T H E I N V E N T I O N Alpha DaRT: a source designed to extend alpha radiation's reach. 8 H E A L T H Y T I S S U E T U M O R Ra-224 source daughter atoms disperse millimeters into the tumor Radium-224 Radon-220 Polonium-216 Lead-212 Bismuth-212 Lead-208 (stable) Four alpha emissions along the decay chain · ²²⁴Ra half-life ~3.7 days 01 A source thinner than a grain of rice, impregnated with Radium- 224, is inserted into the tumor. The radium stays attached to the source. 02 Its short-lived daughter atoms detach and disperse millimeters through the tumor, designed to deliver cytotoxic alpha-particle payloads as they decay. 03 The chain ends in stable, inert atoms. With a ~3.7-day half-life, the treatment switches itself off within about two weeks: no retrieval of activity required. A platform, not a product: one source technology for any solid tumor a needle can reach: skin · head & neck · pancreas · prostate · brain · lung · liver Designed to destroy tumor tissue while sparing surrounding healthy tissue. Investigational in the U.S.; marketing authorizations granted in Israel (skin & oral-cavity SCC) and Japan (unresectable locally advanced / locally recurrent head & neck).

T H E S C I E N C E · I N M O T I O N Alpha DaRT diffusion, animated. 9 Animation is a schematic illustration of the intended mechanism; designed to deliver alpha radiation locally. Not drawn to scale.


0 2 · C L I N I C A L · R E G A I N T R I A L · S N O 2 0 2 6 REGAIN: interim results as of Nov 11, 2026. 11

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY REGAIN trial design. Prospective, interventional, open-label, single-arm study · NCT06910306 · patients treated to date at The Ohio State University Comprehensive Cancer Center 12 20 patients planned sample size of the study 8 patients treated to date all eight alive as of Nov 11, 2026 6 reached response assessment reported in the interim analysis at SNO 12 mo planned follow-up per patient Endpoints Primary: feasibility (deployment of all planned sources with planned tumor dose coverage) and safety (serious adverse events within 90 days) Secondary: radiographic tumor response (RANO criteria) and overall survival Eligibility Recurrent glioblastoma (IDH-wildtype, grade 4 glioma) Up to 3 recurrences Tumor smaller than 3 cm Prior course of central nervous system radiation Treatment Stereotactic intratumoral implantation of titanium sources loaded with radium-224, using the Alpha radial applicator Image-guided placement through minimally invasive burr-hole access, without requiring open craniotomy Enrollment and patient status are interim results as of November 11, 2026. Study design as presented at the SNO 2026 Annual Meeting (Palmer JD et al.). Early, small-sample data are not predictive of final or pivotal results.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Interim results as of Nov 11, 2026. Key takeaways · 8 patients treated, 6 reached response assessment 13 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 100% feasibility all planned sources deployed in 8 of 8 treated patients 0 unanticipated serious adverse events to date · 1 grade 3 SAE (seizure), resolved 8/8 patients alive median overall survival not reached 6.9 mo median follow-up range 3.1 to 11.6 months · from enrollment, six assessed patients 6/6 objective response rate best overall response · 5 complete, 1 partial Survival from enrollment 6.9 months median follow-up in the six assessed patients 3.1 to 11.6 months range of follow-up Three patients followed for more than eight months Best overall response (n = 6) 5 complete responses (83.3%): 3 confirmed, 2 awaiting confirmation 1 partial response (16.7%): 58% decrease in tumor measurements, awaiting confirmation No recurrence in the treated area; 1 patient with progression away from it Still being evaluated Necrosis or suspected necrosis, all asymptomatic, on follow-up imaging in 4 of 6 patients In 2 patients new enhancement near or outside the treated area cannot yet be called necrosis or progression More scans over the coming months; one biopsy planned Interim results as of November 11, 2026. Early, small-sample data are not predictive of final or pivotal results. Alpha DaRT is investigational in the U.S. and has not been approved by the FDA. Confirmed / awaiting confirmation per the principal investigator; response per RANO on serial MRI.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Primary endpoints: feasibility and safety. Interim results as of Nov 11, 2026 · eight patients treated 14 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 100% feasibility Alpha DaRT sources deployed as planned in 8 of 8 treated patients 0 unanticipated serious adverse events to date, in 8 treated patients 1 grade 3 serious adverse event seizure with Todd's paralysis · resolved · first reported in May 2026 The grade 3 event Previously reported in May 2026 Seizure with Todd's paralysis within 10 days of implantation, in a patient with a prior history of seizures Required a 48-hour hospital stay and resolved with steroids Recovery All patients recovered from any adverse events without residual procedure-related symptoms Also reported in May 2026: a grade 2 seizure three days after the procedure in patient 3, resolved with steroids Radiation necrosis on imaging Seen or suspected on follow-up scans in 4 of 6 assessed patients Asymptomatic in all cases; none was a serious adverse event Patient 3 is being treated with bevacizumab; bevacizumab is planned for patient 5 Interim results as of November 11, 2026. Early, small-sample data are not predictive of final or pivotal results. Alpha DaRT is investigational in the U.S. and has not been approved by the FDA. Safety endpoint: serious adverse events within 90 days of implantation; patients 6, 7 and 8 have not yet completed 90 days.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Survival: all eight patients are alive. Interim results as of Nov 11, 2026 · follow-up from trial enrollment · six patients who have reached response assessment 15 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 0 3 6 9 12 Months from enrollment Patient 1 11.6 mo CR, confirmed Patient 2 10.0 mo CR, confirmed Patient 3 8.5 mo CR, confirmed Patient 4 5.3 mo PR, unconfirmed Patient 5 4.6 mo CR, unconfirmed Patient 6 3.1 mo CR, unconfirmed Progression away from treated area Enrollment to treatment After treatment Alive at Nov 11, 2026 Progression away from treated area 8/8 patients alive all treated patients 6.9 mo median follow-up range 3.1 to 11.6 months Not reached median overall survival six assessed patients Interim results as of November 11, 2026. Early, small-sample data are not predictive of final or pivotal results. Alpha DaRT is investigational in the U.S. and has not been approved by the FDA. Patients 7 and 8 have been treated and are alive; they have not yet reached response assessment and are not shown. CR = complete response; PR = partial response (best overall response).

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Response and status by patient. Interim results as of Nov 11, 2026 · best overall response per RANO on serial MRI 16 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 Patient Treated Best overall response Follow-up imaging Recurrence in treated area Outside treated area Status 1 12/05/2025 Complete response, confirmed No measurable disease at treated site None reported Progression at 9 months; re-irradiated, on lomustine Alive 2 02/03/2026 Complete response, confirmed Necrosis since 07/2026; no avid or measurable disease None reported None reported Alive 3 03/27/2026 Complete response, confirmed (previously stable disease at 1 month) Large necrotic lesion, no measurable disease; on bevacizumab None reported New enhancement 10/2026, attributed to developing radiation injury from prior radiation before Alpha DaRT Alive 4 06/24/2026 Partial response (58% decrease), unconfirmed Progressive regional enhancement on 10/16/2026 None reported Necrosis vs. progression not yet determined; biopsy planned Alive 5 07/08/2026 Complete response at 1 month, unconfirmed Mixed necrosis and possible progression at 3 months None reported Possible marginal progression vs necrosis; bevacizumab planned Alive 6 09/09/2026 Complete response at 1 month, unconfirmed No measurable disease at the sources None reported None reported Alive Interim results as of November 11, 2026. Early, small-sample data are not predictive of final or pivotal results. Alpha DaRT is investigational in the U.S. and has not been approved by the FDA. Patients 7 and 8: treated, alive, not yet at response assessment. Per- patient detail as provided by the investigators; items marked TBC are being confirmed with OSU.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Reading the scans: necrosis or recurrence? Interim results as of Nov 11, 2026 · why some of the follow-up imaging cannot yet be interpreted. Any necrosis has been asymptomatic 17 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 1 Necrosis is a known effect. Focal radiation can injure tissue in and around the treated area (radiation necrosis), particularly in brain that has already been irradiated. Every patient in REGAIN has had prior radiation. 2 On MRI it can look like tumor. Necrosis and recurrent tumor both show up as new or growing enhancement. PET, perfusion imaging, the response to bevacizumab and, where needed, a biopsy help to tell them apart. 3 Time usually settles it. Necrosis often stabilizes or improves, on its own or with treatment such as bevacizumab; tumor generally keeps growing. Further scans over the coming months, and one planned biopsy, are expected to clarify the open cases. Patient What the scans show Current read What will tell us 2 Necrosis at the treated site since 07/2026 Necrosis, no tumor: no avid or measurable disease Continued surveillance 3 Large necrotic lesion at the implant site; new enhancement in the right frontal lobe (10/12/2026) Necrosis, no measurable tumor; separate focus attributed to developing radiation injury from prior radiation Continued scans on bevacizumab 4 Progressive regional enhancement and perfusion with PET uptake, outside the expected treatment zone (10/16/2026) Not yet determined: necrosis or progression Planned biopsy; next scans 5 Mixed picture at 3 months (10/09/2026): necrosis around the cavity, a focal area of PET uptake and new enhancement Not yet determined: necrosis or marginal progression Next scans; bevacizumab planned Interim results as of November 11, 2026. Necrosis has been asymptomatic in all cases to date. Patients 1 and 6: no necrosis reported. Patient 1 had progression away from the treated area. Assessments by the investigators as of Nov 11, 2026; they may change as further scans are obtained.

0 3 · R E G A I N · I N T E R I M R E S U L T S A S O F N O V 1 1 , 2 0 2 6 Patient by patient: imaging and clinical course. 18

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Baseline characteristics: six patients. Interim results as of Nov 11, 2026 · all six: WHO grade 4 glioma, IDH wild type · 5 male, 1 female · ages 45 to 71 19 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Enrolled 11/24/2025 01/12/2026 02/26/2026 06/04/2026 06/25/2026 08/10/2026 Treated 12/05/2025 02/03/2026 03/27/2026 06/24/2026 07/08/2026 09/09/2026 Follow-up from enrollment to Nov 11 interim 11.6 months 10.0 months 8.5 months 5.3 months 4.6 months 3.1 months Age, years 56 71 56 57 45 71 Sex Male Male Male Male Male Female MGMT promoter methylation Not assessed: insufficient material Hypermethylated Hypermethylated, at/near assay cutoff Unmethylated Unmethylated Hypermethylated Initial diagnosis date 02/11/2024 06/03/2021 02/12/2025 03/01/2023 12/26/2025 11/25/2024 Number of recurrences 3 2 1 1 2 1 Interim results as of November 11, 2026. Source: REGAIN interim analysis as presented at the SNO 2026 Annual Meeting (Palmer JD et al.). Follow-up measured from enrollment to Nov 11, 2026.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 1: complete response, later progression elsewhere. 56-year-old male · MGMT not assessed · 3 recurrences · enrolled 11/24/2025 · treated 12/05/2025 · follow-up 11.6 months from enrollment 20 PATIENT 1 · 2 · 3 · 4 · 5 · 6 Clinical course 12/05/2025: Alpha DaRT implantation, 100 GyE 1 and 3 months: complete response, no measurable disease at the treated site (first reported in May 2026). 09/18/2026: MRI and PET show multifocal progression away from the treated area, about nine months after treatment. Per the investigator this is not regrowth of the treated tumor. 10/01 to 10/14/2026: third course of radiation, 35 Gy. 10/19/2026: started lomustine. Best overall response Complete response, confirmed Status as of Nov 11, 2026 Alive · no recurrence in the treated area · progression elsewhere, on further therapy MRI 09/18/2026 PET 09/18/2026 Interim results as of November 11, 2026. Images and clinical course as provided by the investigators. Image dates in brackets are to be confirmed with OSU. Individual responses are not predictive of results in other patients.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 2: complete response, with necrosis. 71-year-old male · MGMT hypermethylated · 2 recurrences · enrolled 01/12/2026 · treated 02/03/2026 · follow-up 10.0 months from enrollment 21 PATIENT 1 · 2 · 3 · 4 · 5 · 6 Clinical course 02/03/2026: Alpha DaRT implantation, right frontal, 100 GyE. Day 10: grade 3 seizure with Todd's paralysis in a patient with a history of seizures; 48-hour hospital stay, resolved with steroids. 1 and 3 months: complete response (first reported in May 2026). 07/2026: radiation necrosis identified at the treated site. 09/22/2026: last MRI shows necrosis and no progression; no avid or measurable disease. 10/02/2026: last follow-up, alive. Best overall response Complete response, confirmed Status as of Nov 11, 2026 Alive · necrosis at the treated site, no evidence of tumor · no recurrence MRI, with 28.0 x 26.9 mm measurement 09/22/2026 PET 09/22/2026 Interim results as of November 11, 2026. Images and clinical course as provided by the investigators. Image dates in brackets are to be confirmed with OSU. Individual responses are not predictive of results in other patients.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 3: stable disease converted to complete response. 56-year-old male · MGMT hypermethylated, at/near assay cutoff · 1 recurrence · enrolled 02/26/2026 · treated 03/27/2026 · follow-up 8.5 months from enrollment 22 PATIENT 1 · 2 · 3 · 4 · 5 · 6 Clinical course 03/27/2026: Alpha DaRT implantation, 100 GyE. Day 3: grade 2 seizure with pseudoprogression on MRI, resolved with steroids (reported in May 2026). 1 month: stable disease, 30% decrease. Later scans: no measurable tumor at the implant site, complete response. 10/12/2026: MRI shows a large necrotic lesion at the implant site and new enhancement in the right frontal operculum and subcortical right frontal lobe (arrows). Since then: on bevacizumab for asymptomatic necrosis. Per the investigator, a separate focus with very low PET uptake resolved on bevacizumab and is now attributed to radiation injury from prior radiotherapy before Alpha DaRT. 11/03/2026: last follow-up, alive, local control maintained. Best overall response Complete response, confirmed Status as of Nov 11, 2026 Alive · necrosis, on bevacizumab · separate enhancement attributed to radiation injury from prior radiation MRI at 1 month: 30% decrease in size 05/03/2026 MRI: complete response 10/12/2026 MRI: new enhancement (arrow) 10/12/2026 Interim results as of November 11, 2026. Images and clinical course as provided by the investigators. Image dates in brackets are to be confirmed with OSU. Individual responses are not predictive of results in other patients.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 4: partial response, now under evaluation. 57-year-old male · MGMT unmethylated · 1 recurrence · enrolled 06/04/2026 · treated 06/24/2026 · follow-up 5.3 months from enrollment 23 PATIENT 1 · 2 · 3 · 4 · 5 · 6 Clinical course 06/24/2026: Alpha DaRT implantation, 100 GyE. First assessment: partial response, 58% decrease in tumor measurements. 10/16/2026: MRI shows progressive regional enhancement and increased perfusion, matching areas of Axumin PET uptake in the right temporal, parietal and occipital lobes, significantly outside the expected treatment zone. Open question: necrosis or progression cannot yet be determined. A repeat biopsy is planned. 10/30/2026: last follow-up, alive. Best overall response Partial response (58% decrease), unconfirmed Status as of Nov 11, 2026 Alive · may be reclassified as progression, depending on biopsy and next scans MRI 10/16/2026 MRI: regional enhancement (arrow) 10/16/2026 Axumin PET 10/16/2026 Interim results as of November 11, 2026. Images and clinical course as provided by the investigators. Image dates in brackets are to be confirmed with OSU. Individual responses are not predictive of results in other patients.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 5: complete response at one month, now under evaluation. 45-year-old male · MGMT unmethylated · 2 recurrences · enrolled 06/25/2026 · treated 07/08/2026 · follow-up 4.6 months from enrollment 24 PATIENT 1 · 2 · 3 · 4 · 5 · 6 Clinical course 07/08/2026: Alpha DaRT implantation, 100 GyE. 1 month: complete response, no measurable enhancement; PET shows no avidity at the sources. 10/09/2026 (3 months): mixed picture of necrosis and possible progression: focal PET uptake (SUV 6.2), increased perfusion and FLAIR signal, and new enhancement in the optic area. PET signal is gone at the level of the sources, with necrosis around the cavity. Open question: possible marginal progression anterior to the implant, on the far side of the resection cavity and outside the treatment field, versus necrosis. Bevacizumab is planned. 10/22/2026: last follow-up, alive. Best overall response Complete response at 1 month, unconfirmed Status as of Nov 11, 2026 Alive · necrosis vs progression at the margin not yet determined Pre-implant 07/07/26 1 month 08/08/26 MRI, 3 months 10/09/2026 PET, 3 months 10/09/2026 Interim results as of November 11, 2026. Images and clinical course as provided by the investigators. Image dates in brackets are to be confirmed with OSU. Individual responses are not predictive of results in other patients.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Patient 6: complete response at first assessment. 71-year-old female · MGMT hypermethylated · 1 recurrence · enrolled 08/10/2026 · treated 09/09/2026 · follow-up 3.1 months from enrollment 25 PATIENT 1 · 2 · 3 · 4 · 5 · 6 Clinical course 09/09/2026: Alpha DaRT implantation, 100 GyE, into a left temporal tumor. One bi-lobed lesion, treated through two trajectories. First assessment: complete response at each site, no measurable disease at the sources. Currently: no symptoms. Best overall response Complete response, unconfirmed Status as of Nov 11, 2026 Alive · no symptoms · awaiting confirmation on the next scan Pre-implant 09/08/26 After implant 09/09/26 1 month Follow Up 10/09/26 Pre-implant 09/08/26 After implant 09/09/26 1 month Follow Up 10/09/26 Interim results as of November 11, 2026. Images and clinical course as provided by the investigators. Image dates in brackets are to be confirmed with OSU. Individual responses are not predictive of results in other patients.

REGAIN DESIGN · OVERVIEW · ENDPOINTS · SURVIVAL · RESPONSE · SCANS · BASELINE · PATIENTS · SUMMARY Summary: interim results as of Nov 11, 2026. REGAIN · presented at the SNO 2026 Annual Meeting 26 PRESENTED AT THE SNO 2026 Annual Meeting · Philadelphia, Nov 12-15 What the data show Feasible: all planned sources deployed in 8 of 8 patients (100%) Safety: no unanticipated serious adverse events; one grade 3 seizure, resolved Survival: all 8 patients alive; median follow- up 6.9 months from enrollment (3.1 to 11.6); median overall survival not reached Response: 6 of 6 objective responses; 5 complete, 1 partial What is still being evaluated Necrosis, all asymptomatic, seen or suspected on follow-up imaging in 4 of 6 patients In 2 patients it is too early to tell necrosis from progression near or outside the treated area 1 patient has progressed away from the treated area; no recurrence reported within it What comes next More scans over the coming months, and one planned biopsy, expected to clarify the open imaging questions Continue enrollment toward 20 patients Longer follow-up on durability of response and survival Additional interim data anticipated in early 2027 Interim results as of November 11, 2026. Early, small-sample data are not predictive of final or pivotal results. Alpha DaRT is investigational in the U.S. and has not been approved by the FDA. Anticipated timing is forward-looking and subject to change.

A N T I C I P A T E D M I L E S T O N E S The next few months. Anticipated milestones · today's discussion: recurrent GBM 27 H 2 2 0 2 6 H 1 2 0 2 7 Skin: ReSTART pivotal Pancreas: IMPACT pilot GBM: REGAIN pilot Prostate: U.S. pilot Top-line data: Early 2027 → potential FDA submission ✓ Recruitment complete (Q3) Initial data: early 2027 Additional data (SNO 2026) Today's discussion Additional interim data: early 2027 First patient treated Timings are targets, deliberately expressed as ranges; all milestones are forward-looking, contingent and subject to change, and regulatory submission or approval is not assured.

Questions? alphatau.com · NASDAQ / TASE: DRTS · IR@alphatau.com 28